CN122520749A - 优化的gip肽类似物 - Google Patents

优化的gip肽类似物

Info

Publication number
CN122520749A
CN122520749A CN202610465590.8A CN202610465590A CN122520749A CN 122520749 A CN122520749 A CN 122520749A CN 202610465590 A CN202610465590 A CN 202610465590A CN 122520749 A CN122520749 A CN 122520749A
Authority
CN
China
Prior art keywords
gip
seq
amino acid
peptide
a13aib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202610465590.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·M·罗森基尔德
A·H·斯巴尔-乌尔里希
D·里伯
S·J·三尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by Individual filed Critical Individual
Publication of CN122520749A publication Critical patent/CN122520749A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202610465590.8A 2019-12-03 2020-12-03 优化的gip肽类似物 Pending CN122520749A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EPPCT/EP2019/083506 2019-12-03
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EP20179259 2020-06-10
EP20179259.5 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues
CN202080083881.1A CN114761420B (zh) 2019-12-03 2020-12-03 优化的gip肽类似物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080083881.1A Division CN114761420B (zh) 2019-12-03 2020-12-03 优化的gip肽类似物

Publications (1)

Publication Number Publication Date
CN122520749A true CN122520749A (zh) 2026-08-07

Family

ID=71083547

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202610465590.8A Pending CN122520749A (zh) 2019-12-03 2020-12-03 优化的gip肽类似物
CN202080083881.1A Active CN114761420B (zh) 2019-12-03 2020-12-03 优化的gip肽类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080083881.1A Active CN114761420B (zh) 2019-12-03 2020-12-03 优化的gip肽类似物

Country Status (10)

Country Link
US (1) US20250346647A2 (cg-RX-API-DMAC7.html)
EP (1) EP4069719A1 (cg-RX-API-DMAC7.html)
JP (2) JP7788376B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220108064A (cg-RX-API-DMAC7.html)
CN (2) CN122520749A (cg-RX-API-DMAC7.html)
AU (1) AU2020398675A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157387A1 (cg-RX-API-DMAC7.html)
IL (1) IL293249A (cg-RX-API-DMAC7.html)
MX (1) MX2022006737A (cg-RX-API-DMAC7.html)
WO (1) WO2021110845A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023014740A (es) * 2021-06-10 2024-03-13 Antag Therapeutics Aps Tratamiento de la obesidad y trastornos relacionados con la obesidad.
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
CN117402219B (zh) 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
AR134436A1 (es) * 2023-11-22 2026-01-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario
TW202615088A (zh) * 2024-06-14 2026-04-16 美商美國禮來大藥廠 用於改善胰島素敏感性之組合物及方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
JP5399244B2 (ja) * 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド
CA2732949C (en) * 2008-08-07 2016-12-20 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (es) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN103003300B (zh) * 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues
US11572399B2 (en) * 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US12187773B2 (en) * 2018-12-03 2025-01-07 Antag Therapeutics Aps Modified GIP peptide analogues

Also Published As

Publication number Publication date
US20250346647A2 (en) 2025-11-13
MX2022006737A (es) 2022-06-14
US20230416330A1 (en) 2023-12-28
JP2023505441A (ja) 2023-02-09
JP2025172864A (ja) 2025-11-26
IL293249A (en) 2022-07-01
CN114761420B (zh) 2026-04-28
CA3157387A1 (en) 2021-06-10
JP7788376B2 (ja) 2025-12-18
KR20220108064A (ko) 2022-08-02
EP4069719A1 (en) 2022-10-12
AU2020398675A1 (en) 2022-05-26
CN114761420A (zh) 2022-07-15
WO2021110845A1 (en) 2021-06-10

Legal Events

Date Code Title Description
PB01 Publication